Comparison

“GLOW” vs “KLOW”:
two peptide mixes compared

Two seller names for pre-mixed vials that differ by one peptide. The same questions asked of both: what each lists, what the fourth component adds to the published record, and where each component stands with regulators and in sport. We found no study of either mix, so this page gives no verdict.

Short answerCompound research · 6 min read · Updated 21 Nov 2026

GLOW and KLOW are seller names for pre-mixed vials. GLOW lists three peptides, GHK-Cu, BPC-157 and TB-500, and KLOW adds a fourth, KPV. We found no published study or registered trial of either mix, and none comparing them (21 November 2026). KPV’s own research is in mice and cells; FDA staff found no clinical studies of it.

Key takeaways

  • GLOW is a seller name for one vial mixing GHK-Cu, BPC-157 and TB-500; KLOW is the same mix with a fourth peptide, KPV.
  • We found no published study or registered trial of either mix, and no study comparing the two (PubMed and ClinicalTrials.gov, 21 Nov 2026).
  • What the fourth component adds is KPV’s own record: a 2008 mouse and cell study, with no clinical studies or human exposure data found by FDA staff.
  • HHS’s draft compounding policy of October 2026, which is not an approval, lists BPC-157, TB-500 and KPV but not GHK-Cu, and covers single-ingredient products only.
  • WADA names BPC-157 and TB-500 as prohibited at all times; it does not name GHK-Cu or KPV, and says a peptide not specifically named “may still be prohibited”.

01GLOW and KLOW side by side

The same questions, asked of both names. Dated 21 November 2026.

QuestionGLOWKLOW
What the name refers toA seller name for one vial that mixes three peptidesA seller name for one vial that mixes four peptides
Listed componentsGHK-Cu, BPC-157, TB-500GHK-Cu, BPC-157, TB-500, KPV
Studied as a mixNo study found, in any speciesNo study found, in any species
Compared with the otherNo study foundNo study found
Evidence tier of the studies cited here, component by componentGHK-Cu: small skin studies in people (T2), plus animal and cell studies. BPC-157: small human studies (T2) and animal studies (T3). TB-500: animal and cell studies (T3, T4)The same three, plus KPV: a mouse and cell study (T3, T4)
Human data for the component that differsNo fourth componentFDA staff found no clinical studies or human exposure data for KPV
United StatesFDA’s drug database lists no medicine containing GHK-Cu, BPC-157 or TB-500. HHS’s draft compounding policy of October 2026, which is not an approval, lists BPC-157 and TB-500, not GHK-Cu, and covers single-ingredient products onlyThe same, and KPV is on the HHS list too. FDA staff say KPV is not a component of an FDA-approved drug
AustraliaBPC-157 and TB-500 are listed in Schedule 4, prescription-only medicines, and Appendix D of the Poisons Standard October 2026. The TGA says many peptide products promoted online “are unapproved therapeutic goods and may be unlawful to import, supply or advertise”. We searched the Standard for GHK-Cu’s names and found no entry by name; it has group entries for copper compounds. We draw no scheduling conclusion of our ownThe same. The TGA says many peptide products promoted online “are unapproved therapeutic goods and may be unlawful to import, supply or advertise”. We searched the Standard for KPV as well and found no entry by name. We draw no scheduling conclusion of our own
Sport (WADA 2026 and 2027 Lists)BPC-157 (class S0) and TB-500 (class S2.3) are named as prohibited at all times. GHK-Cu is not named, and WADA says a peptide not specifically named “may still be prohibited”The same. KPV is not named either, and WADA says a peptide not specifically named “may still be prohibited”
Identities a lab report has to confirmThreeFour

Each name has its own page: what is the “GLOW peptide”? and what is the “KLOW peptide”?

02What does the fourth component, KPV, add in published research?

One more compound, with its own, thinner record. Nothing about the mix.

Identity

A fourth molecule

KPV is a three-amino-acid peptide, lysine–proline–valine. FDA’s 2026 briefing describes it as a fragment of the hormone α-MSH.

Evidence · mouse and cell

A mouse and cell record

A 2008 study used two chemically induced forms of colitis in mice and three human cell lines, and measured inflammatory signalling. FDA staff found no clinical studies or human exposure data.

Testing

A fourth identity to confirm

A lab report for the four-peptide mix has one more compound to identify and measure. FDA staff assessed two forms of KPV, the free base and the acetate salt, and judged neither well characterised.

What KPV does not add is any study of KPV together with one of the other three. The two papers we found that name it beside GHK-Cu, BPC-157 or TB-500 are reviews (PubMed, 21 November 2026). FDA staff also write that its molecular targets “remain unknown” and that they identified no pharmacokinetic study. The full profile: KPV.

03Has any study compared GLOW and KLOW?

Not that we found. We found no study of either mix on its own, so there is nothing to compare.

On 21 November 2026 we searched PubMed with the component names quoted and unquoted. No paper names all four. Seven papers name GHK-Cu and BPC-157 together with TB-500 or thymosin β4, and each is a review, commentary or letter; none gave the three to cells, animals or people. ClinicalTrials.gov lists no trial that gives two or more of the components together.

That is why this page gives no verdict on which is “better”. There is no measurement to base one on. Evidence attaches to what was studied: peptide blends: one vial, no shared evidence.

04How do regulators and WADA treat each component?

Component by component. None of the status documents we read names either mix.

  1. Sep 2023FDA Category 2

    BPC-157 and TB-500, listed for both mixes, and KPV, listed for KLOW only, enter FDA’s list of compounding substances that raise significant safety risks.

  2. 22 Apr 2026Out of Category 2

    HHS records that neither the placement nor the removal changed the status of the three under section 503A.

  3. 14 May 2026GHK-Cu back under evaluation

    FDA’s updated list returns GHK-Cu, listed for both mixes, to Category 1, “except for injectable routes of administration”.

  4. 23–24 Jul 2026Advisory committee meets

    FDA staff propose not adding BPC-157, TB-500 or KPV to the 503A bulks list. HHS records that the committee voted in favour of each.

  5. 1 Oct 2026Poisons Standard October 2026 in force

    Australia’s current standard lists BPC-157 and TB-500 in Schedule 4 and Appendix D.

  6. 30 Oct 2026HHS draft policy published

    It names six peptides, including BPC-157, TB-500 and KPV, and applies only when a product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. The notice calls it a draft that “is not binding”.

  7. 1 Jan 2027WADA 2027 List takes effect

    Its S0 class adds “peptides” to its examples. BPC-157 and TB-500 remain named.

In the UK, the emc database of licensed-medicine information returned no results for any of the four names on 21 November 2026; it is not the full UK register. Country by country, for each component: the KLOW page and the dated tracker, regulatory status. Sport: peptides and anti-doping.

05What we don’t know, and what would have to be studied

There is no evidence to rank one mix above the other. These are the studies that would be needed.

1
Stability of each mix

Whether the peptides stay intact together in one vial, and for how long. We found no published data for three peptides or for four.

2
Each mix against its components

The same model and the same measures, with a group for each peptide alone and a group for the mix. A 2026 rat study had a combination group for two of the peptides, BPC-157 and TB-500; we found none for three or four.

3
Three peptides against four

A direct comparison in which KPV is the only difference. We found none, published or registered.

4
Data in people

Controlled studies, starting with how the body absorbs and clears each component. FDA staff identified no pharmacokinetic study of KPV.

How to check what a mixed vial holds: how to read a COA.

This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.

RefSources

  1. PubMed searches (title and abstract; names quoted and unquoted): all four components together, 0 results; (GHK OR “copper tripeptide” OR prezatide) AND (BPC OR pentadecapeptide OR bepecin), 8 results, each a review, commentary or letter; the same with TB-500 or thymosin beta names added, 7; KPV with any of the other three, 3 (two reviews and an unrelated 1995 paper on lactoferrin); KLOW with “peptide”, 0. Database searches, 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=%28GHK%5Btiab%5D+OR+%22copper+…
  2. ClinicalTrials.gov. Searches for the names of GHK-Cu, BPC-157, TB-500 and KPV: no record gives two or more of them together, and no record names KPV as an intervention; NCT07487363 (TB-500, phase 1/2, placebo-controlled, recruiting, no results posted). Registry searches through API v2, 21 Nov 2026. clinicaltrials.gov/study/NCT07487363
  3. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: KPV-related bulk drug substances (KPV free base and KPV acetate). Advisory committee briefing, 2026 (pp. 7–29); read 21 Nov 2026. www.fda.gov/media/193346/download
  4. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026 (pp. 13, 16, 20, 40–47); read 21 Nov 2026. www.fda.gov/media/193343/download
  5. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: TB-500-related bulk drug substances. Advisory committee briefing, 2026 (pp. 7, 10, 15–16, 21, 25–34); read 21 Nov 2026. www.fda.gov/media/193349/download
  6. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 21 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  7. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3), including the GHK-Cu update. List updated 14 May 2026; read 21 Nov 2026. www.fda.gov/media/94155/download
  8. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, Oct 2026; read 21 Nov 2026 on the Internet Archive capture of 15 Nov 2026, the newest complete one (hhs.gov returned 403 to our tools). web.archive.org/web/20261115103435/https://www.hhs.gov/sites…
  9. Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026; text read on govinfo 21 Nov 2026. www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.ht…
  10. U.S. Food and Drug Administration. Drugs@FDA data through the openFDA API (data last updated 20 Nov 2026): no product matches BPC-157, BPC, pentadecapeptide, TB-500, thymosin, timbetasin, KPV, prezatide, GHK or copper tripeptide as a brand, generic, substance or active-ingredient name (control search, somatropin: 12 records). Database queries, 21 Nov 2026. api.fda.gov/drug/drugsfda.json?limit=1
  11. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327): Schedule 4 and Appendix D, clause 5. Federal Register of Legislation, registered 30 Sep 2026, commenced 1 Oct 2026; as-made text searched 21 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  12. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 Sep 2026; read 21 Nov 2026 on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au did not respond to our tools). web.archive.org/web/20261105200754/https://www.tga.gov.au/re…
  13. World Anti-Doping Agency. Prohibited List 2027 (in force 1 Jan 2027), classes S0 and S2.3; the 2026 List (in force 1 Jan 2026) was read beside it. International Standard; both PDFs downloaded and searched 21 Nov 2026. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  14. World Anti-Doping Agency. 2027 Prohibited List: summary of major modifications and explanatory notes (S0, non-approved substances). Undated in its text; read at wada-ama.org 21 Nov 2026. www.wada-ama.org/sites/default/files/2026-09/2027_list_expla…
  15. Electronic medicines compendium (emc). Searches for KPV, BPC-157, BPC 157, TB-500, thymosin, GHK, copper tripeptide and prezatide: “No search results” for each (control search, somatropin: 21 results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=KPV
  16. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. [Mouse colitis and cell study of KPV.] Gastroenterology, 2008;134(1):166–178. PMID 18061177. Read 21 Nov 2026. pmc.ncbi.nlm.nih.gov/articles/PMC2431115/
  17. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171. Abstract read through NCBI E-utilities, 21 Nov 2026 (the PubMed page returned a cookie notice to our tools). eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&…
  18. Pickart L, Margolina A. [Review of GHK-Cu research by its discoverer.] Int J Mol Sci, 2018;19(7):1987. PMID 29986520. Read 21 Nov 2026. pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  19. Biçer O, Adanir O, Güleryüz Y, et al. [Rat Achilles tendon repair study of BPC-157, TB-500 and both together.] Jt Dis Relat Surg, 2026;37(3):822–837. PMID 42542926. Read 21 Nov 2026. doi.org/10.52312/jdrs.2026.2951

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

What is the difference between GLOW and KLOW?

One peptide. GLOW is a seller name for a vial mixing GHK-Cu, BPC-157 and TB-500; KLOW is the same mix with KPV added.

Has any study compared GLOW and KLOW?

Not that we found (PubMed and ClinicalTrials.gov, 21 Nov 2026). We found no study of either mix on its own either, so there is no evidence to rank one above the other.

What does KPV add to the published research?

Its own record, which is a mouse and cell study from 2008. FDA staff found no clinical studies or human exposure data for KPV, and we found no study of it together with the other three.

Are the components of GLOW and KLOW prohibited in sport?

WADA’s Prohibited List names BPC-157 (class S0) and TB-500 (class S2.3) as prohibited at all times. It does not name GHK-Cu or KPV, and WADA says a peptide not specifically named “may still be prohibited”.

Does a lab report for KLOW have to show more than one for GLOW?

Yes, one more compound. A report for a mixed vial has to identify and measure each peptide on its own: three for GLOW, four for KLOW.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page